EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis—Reply

Mark G Lebwohl, Adelaide A Hebert, Melinda J Gooderham

JAMA · 2023

DOI: 10.1001/jama.2022.22649 ↗

Kurz gefasst

Leserbrief in der Zeitschrift JAMA, 2023. Verfasst von Mark G Lebwohl und 2 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, New York. Hauptthemen laut MEDLINE: Phosphodiesterase 4 Inhibitors, Psoriasis. Die Arbeit nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphodiesterase 4 InhibitorsPsoriasisHumansAdministration, CutaneousAminopyridinesBenzamidesChronic DiseaseCyclopropanesDouble-Blind MethodSeverity of Illness IndexSkin CreamTreatment Outcome

Substanzen

AminopyridinesBenzamidesCyclopropanesPhosphodiesterase 4 InhibitorsRoflumilast

Autor:innen und Institutionen

  • Icahn School of Medicine at Mount Sinai, New York, New York.
  • SkiN Centre for Dermatology, Peterborough, Ontario, Canada.
  • McGovern Medical School at UTHealth Houston, Houston, Texas.

Zitieren

APA

Lebwohl, M. G., Hebert, A. A., & Gooderham, M. J. (2023). Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis—Reply. JAMA. https://doi.org/10.1001/jama.2022.22649

Vancouver

Lebwohl MG, Hebert AA, Gooderham MJ. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis—Reply. JAMA. 2023. doi:10.1001/jama.2022.22649

BibTeX
@article{Lebwohl2023,
  author = {Lebwohl, Mark G and Hebert, Adelaide A and Gooderham, Melinda J},
  title = {Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis—Reply},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2022.22649}
}
Kostenlos starten →